• Explore /
  • Poster
  • / A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.

A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.

Abstract Poster

Authors

Enrique Grande

Enrique Grande

Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain

Enrique Grande , Daniel E. Castellano , Ana B. Custodio , Rocio Garcia-Carbonero , Encarnación González , Carlos López-López , Javier Munarriz , Isabel Sevilla , Alexandre Teule , Marta Benavent Viñuales , Teresa Alonso , Pablo Gajate Borau , José Palacios , Jaume Capdevila

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02402062

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS479)

DOI

10.1200/jco.2016.34.4_suppl.tps479

Abstract #

TPS479

Poster Bd #

O7

Abstract Disclosures

Similar Posters

First Author: Jaume Capdevila

First Author: J. Garcia-Donas

First Author: Enrique Grande

First Author: Huaying Wang